Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Frye

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Chemistry & Biology|January 16, 1999
Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic eraS V Frye
Clinical Pharmacology and Therapeutics|February 14, 2013
Targeting chromatin readersL I James, S V Frye
Biochemistry|October 17, 1995
Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energiesG Tian, R A Mook, M L Moss, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 1997
Unique preclinical characteristics of GG745, a potent dual inhibitor of 5ARH N Bramson, D Hermann, K W Batchelor, et al.
Pharmaceutical Biotechnology|October 7, 1998
Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductaseS V Frye, H N Bramson, D J Hermann, et al.
Biochemistry|March 19, 1996
Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanismM L Moss, P Kuzmic, J D Stuart, et al.
Journal of Medicinal Chemistry|December 24, 1993
6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductaseS V Frye, C D Haffner, P R Maloney, et al.
Journal of Medicinal Chemistry|July 22, 1994
6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomeraseS V Frye, C D Haffner, P R Maloney, et al.
Journal of Medicinal Chemistry|July 7, 1995
Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituentS V Frye, C D Haffner, P R Maloney, et al.
Anti-Cancer Drug Design|January 5, 2002
A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activityE Wood, R M Crosby, S Dickerson, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Chemistry & Biology|January 16, 1999
Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic eraS V Frye
Clinical Pharmacology and Therapeutics|February 14, 2013
Targeting chromatin readersL I James, S V Frye
Biochemistry|October 17, 1995
Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energiesG Tian, R A Mook, M L Moss, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 1997
Unique preclinical characteristics of GG745, a potent dual inhibitor of 5ARH N Bramson, D Hermann, K W Batchelor, et al.
Pharmaceutical Biotechnology|October 7, 1998
Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductaseS V Frye, H N Bramson, D J Hermann, et al.
Biochemistry|March 19, 1996
Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanismM L Moss, P Kuzmic, J D Stuart, et al.
Journal of Medicinal Chemistry|December 24, 1993
6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductaseS V Frye, C D Haffner, P R Maloney, et al.
Journal of Medicinal Chemistry|July 22, 1994
6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomeraseS V Frye, C D Haffner, P R Maloney, et al.
Journal of Medicinal Chemistry|July 7, 1995
Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituentS V Frye, C D Haffner, P R Maloney, et al.
Anti-Cancer Drug Design|January 5, 2002
A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activityE Wood, R M Crosby, S Dickerson, et al.
Pageof 2